Pre-treatment with rLH (Luveris 75 IU),

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Infertility, Female

View Full Landscape

Drug Information

Target Indication

Infertility, Female

Clinical Trial

NCT03741699

Last updated: 8/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/29/2000

Luveris

Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/l.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vericiguat tabletPhase 3

Heart Failure

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic